Core Viewpoint - The collaboration between Insilico Medicine (03696) and Qilu Pharmaceutical Group aims to accelerate the development of innovative therapies for cardiovascular and metabolic diseases, with a total agreement value exceeding HKD 931 million [1] Group 1: Collaboration Details - Insilico Medicine has signed a strategic drug development cooperation agreement with Qilu Pharmaceutical and its subsidiary Shanghai Qilu Pharmaceutical Research Center [1] - The partnership will leverage Insilico's proprietary Pharma.AI solution to develop small molecule inhibitors targeting specific pathways in the management of cardiovascular and metabolic diseases [1] Group 2: Financial Aspects - The agreement includes milestone payments for development and sales, as well as a share of subsequent net sales based on unit numbers [1] - The total value of the agreement is over HKD 931 million, indicating significant financial commitment from both parties [1]
英矽智能(03696)与齐鲁制药达成超过9.31亿港元的药物研发合作 加速心血管与代谢类疾病创新疗法开发